Review Article
Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
Table 1
Clinicopathological Features of TNBC versus BLBC versus BRCA-associated Breast Cancer.
| Characteristics | Triple-negative breast cancer | Basal-like breast cancer | BRCA-associated breast cancer |
| Receptor status | Negative | Negative | Often negative | HER2 Status | Negative | Negative | Negative | Cytokeratin 5/6, 17 | Often positive | Positive | Often positive | EGFR expression | Often positive | Often positive | Often positive | p53 | Often mutated | Often mutated | Often mutated | BRCA status | May be dysfunctional secondary to diminished expression or increased expression of negative regulators of the BRCA pathway | May be dysfunctional secondary to diminished expression or increased expression of negative regulators of the BRCA pathway | Inactivated secondary to a hereditary mutation | Molecular gene expression profile | Often basal-like | Basal-like | Often basal-like | Histology | Ductal/poorly differentiated/high grade | Ductal/poorly differentiated/high grade | Ductal/poorly differentiated/high grade |
|
|